Archives

– ISA101b and cemiplimab studied in patients with platinum
refractory HPV16-positive oropharyngeal cancer (OPC)

Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals
B.V., a clinical-stage company dedicated to the development of rationally
designed immunotherapeutics, today announced randomization of the first
patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810).

This double blind, placebo-controlled, randomized,
phase 2 study (NCT03669718) will enroll approximately 164 patients with HPV16-positive oropharyngeal cancer (OPC), who have failed first-line chemotherapy. Patients will be randomly allocated on a 1:1 basis to the combination of cemiplimab/ISA101b or cemiplimab/placebo. In both study arms,

Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology
company, today announced that its Chief Scientific Officer Prof. Cornelis
Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in
Vancouver, BC, Canada, January 20-24, 2019.

The talk titled
“Therapeutic HPV16 Vaccination Is Effective as Monotherapy in
Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced
Cancers” is scheduled for Thursday, January 24, 2019, at 17:00 as part of the
session “Immune Monitoring of T Cells” (17:00-18-45, Pacific Ballroom).

The data will
outline the T cell response to ISA Pharmaceuticals´ therapeutic vaccine ISA101 and
the resulting clinical activity. ISA101 is directed against the HPV16 oncoproteins
E6/E7 and

-Ceremony Conventio Medicinae held at University Medical Center

Leiden, The Netherlands, October 26, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that its Chief Scientific Officer, Prof. Cornelis Melief, has received an honorary doctorate from the University Medical Center of Johannes Gutenberg University Mainz, Germany. The honorary doctorate was awarded during a festive ceremony in Mainz on October 25, 2017.

Prof. Melief was recognized for his lifetime achievements as a pioneer in tumor immunology and his special merits regarding immunological research in Mainz.

“It is a special honor for me to award Prof. Cornelis Melief with the honorary doctorate of

Please find below a link to an interview taken during ESMO in Madrid with Dr Bonnie Glisson on the combination trial of ISA101 and Nivolumab (aPD1) in SCCHN patients run at MD Anderson Cancer Center:
http://www.ascopost.com/videos/2017-esmo-congress/bonnie-s-glisson-md-on-hpv-16plus-cancer-study-results/

– Incurable HPV16+ solid tumors treated with therapeutic cancer vaccine plus checkpoint inhibitor

Leiden, The Netherlands, September 4, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced the presentation of the results of a clinical Phase II trial initiated by MD Anderson Cancer Center in collaboration with ISA and Bristol-Myers Squibb (NCT02426892) at ESMO 2017 (September 8-12, 2017, Madrid, Spain). In the trial, cancer patients with HPV16+ incurable solid tumors received a combination of ISA’s synthetic long-peptide (SLP) HPV-16 vaccine ISA101 and nivolumab, a monoclonal antibody acting as a PD-1 checkpoint inhibitor.

An oral presentation of the results will

-Phase I/II trial shows significant responses of HPV16-positive patients with late-stage cervical cancer

Leiden, The Netherlands, May 23, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that an update of the results of a company-sponsored clinical Phase I/II trial in late-stage cervical cancer patients (ISA101-CervISA) will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017, Chicago, IL, USA).

A poster presentation will be held by Winald Gerritsen MD, PhD., one of the Principle Investigators of the CervISA study, on Thursday, June 3, 2017:

“Poster Session Gynecologic Cancer”: 1:15PM – 4:45PM

The data will be based on the abstract titled

– Cornelis (“Kees”) Melief receives lifetime achievement award for his work as a leading immuno-hematologist

Leiden, The Netherlands, May 11, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that its Chief Scientific Officer Prof. Cornelis (Kees) Melief has received the first ever lifetime achievement award granted by the Association for Cancer Immunotherapy CIMT for his pioneering research on cancer immunotherapy. The ceremony took place at this year´s 15th CIMT Anniversary Symposium in Mainz, Germany.

Kees Melief is professor emeritus at Leiden University Medical Center (LUMC) and the co-founder and CSO of ISA Pharmaceuticals. During his longstanding career, he has

– First data of phase I/II trial in HPV16-positive patients with late-stage cervical cancer

Leiden, The Netherlands, February 16, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that results of a company-sponsored clinical Phase I/II trial in late-stage cervical cancer (ISA101-CervISA) will be presented at the inaugural ASCO-SITC congress on immuno-oncology (February 23-25, 2017, Orlando, FL, USA).

An oral and a poster presentation will be held by Prof. Cornelis Melief and Marij Welters, PhD, on Thursday, February 23, 2017:

“Poster Session A”: 11:30AM-1:00PM and 5:30PM-6:30PM (Cornelis Melief)

“Oral Abstract session A”: 1:00PM-2:15PM (Marij Welters)

The data will be based on the

– Next-generation immunotherapy called MyISA® for individual cancer patients

Leiden, The Netherlands, December 7, 2016 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has joined the recently established Tumor neoantigEn SeLection Alliance (TESLA), a global cancer neoantigen alliance forged by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute, which was announced on December 1st, 2016. Consisting of 30 of the world’s leading research organizations and corporations, the group’s focus will be on developing better predictive models for identifying neoantigens. The initiative will support tests carried out by its members and the consistent improvement of algorithms to analyze tumor

ISA Pharmaceuticals participates in the newly-launched Tumor neoantigEn SeLection Alliance (TESLA), run by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). Read the full press release here:

http://www.parkerici.org/media/2016/parker-institute-for-cancer-immunotherapy-cri-neoantigen-alliance